Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
India · Delayed Price · Currency is INR 1,648.00
-1.80 (-0.11%)
May 11, 2026, 3:30 PM IST
Dr. Lal PathLabs Revenue
In the fiscal year ending March 31, 2026, Dr. Lal PathLabs had annual revenue of 27.63B INR with 12.25% growth. Dr. Lal PathLabs had revenue of 7.03B in the quarter ending March 31, 2026, with 16.61% growth.
Revenue
27.63B
Revenue Growth
+12.25%
P/S Ratio
9.98
Revenue / Employee
5.55M
Employees
4,980
Market Cap
275.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 27.63B | 3.02B | 12.25% |
| Mar 31, 2025 | 24.61B | 2.35B | 10.54% |
| Mar 31, 2024 | 22.27B | 2.10B | 10.40% |
| Mar 31, 2023 | 20.17B | -705.26M | -3.38% |
| Mar 31, 2022 | 20.87B | 5.06B | 32.01% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 568.09B |
| Cipla | 279.67B |
| Apollo Hospitals Enterprise | 242.15B |
| Divi's Laboratories | 103.14B |
| Emcure Pharmaceuticals | 92.16B |
| Piramal Pharma | 88.69B |
| Gland Pharma | 61.13B |
| Krishna Institute of Medical Sciences | 36.27B |
Dr. Lal PathLabs News
- 9 days ago - Dr. Lal PathLabs Ltd (BOM:539524) Q4 2026 Earnings Call Highlights: Strong Revenue Growth Amid ... - GuruFocus
- 10 days ago - Q4 2026 Dr. Lal PathLabs Ltd Earnings Call Transcript - GuruFocus
- 11 days ago - Dr. Lal PathLabs Earnings Call Transcript: Q4 2026 - Transcripts
- 11 days ago - Dr Lal PathLabs records Rs 703 Cr revenue with 16.6% growth in Q4 FY26 - Business Upturn
- 11 days ago - Dr Lal Pathlabs Q4 Results: Profit falls 15% as margin declines nearly 300 bps - Business Upturn
- 12 days ago - Dr. Lal PathLabs Ltd (NSE:LALPATHLAB) Q4 2026: Everything You Need to Know Ahead of Earnings - GuruFocus
- 7 weeks ago - Petronet LNG, HDFC Bank & more: Top stocks to watch today - The Times of India
- 3 months ago - Dr Lal PathLabs share in focus as CLSA sees ~17% upside on volume-led growth - Business Upturn